首页 > 市场调查报告书 > 製药

神经疾病

市场调查报告书

商品编码

1451731

2024-2032年按世代类型、抗癫痫药物类型、配销通路和地区分類的癫痫药物市场

Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2024-2032

出版日期: 2024年03月02日 | 出版商:

IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

2023年全球癫痫药物市场规模达23亿美元。展望未来， IMARC Group预计到2032年市场规模将达到44亿美元，2024-2032年复合年增长率（CAGR）为7.16%。癫痫盛行率的上升、老年人脑癌发生率的增加以及广泛的研发（R&D）活动是推动市场发展的一些关键因素。

癫痫药物是指用于治疗癫痫的药物，癫痫是一种中枢神经系统 (CNS) 疾病，会导致不可预见的、无端的、反覆发作的癫痫发作。癫痫会影响各种精神和身体功能，导致突然的行为改变、感觉、意识丧失和严重的情绪困扰。其药物包括第一代、第二代和第三代抗癫痫药物（AED），例如口服、静脉注射（IV）和肌肉注射途径给药的片剂、胶囊、液体和糖浆。癫痫药物广泛用于治疗各种癫痫发作，包括局部性癫痫发作、难治性癫痫发作、混合性癫痫发作、强直阵挛性癫痫发作和急性反覆癫痫发作。癫痫药物是安全的，具有更好的耐受性，可以预防危及生命的不良反应，并最大限度地减少对认知功能的负面影响。

目前，由于神经系统疾病、产伤、感染、药物滥用和道路伤害发病率的增加，癫痫盛行率不断上升，这是推动市场成长的主要因素之一。癫痫药物广泛用于消除癫痫发作、减少癫痫发作频率、避免长期治疗的不良影响，从而帮助患者恢復正常的心理和职业活动，维持正常的生活方式。除此之外，容易罹患严重疾病（例如可能导致癫痫发作的脑癌）的老年人口数量不断增加，也是另一个主要的生长诱导因素。此外，广泛的研究和开发（R＆D）活动旨在开发新的和先进的药物，这些药物价格实惠，可提高耐受性和疗效，同时减少副作用，目前正在对市场成长产生积极影响。除此之外，最近开发的缓释（ER）药物配方允许更长的给药间隔，同时最大限度地减少血清药物水平的波动，从而与立即释放（IR）药物相比提高疗效和依从性，正在促进市场发展生长。此外，政府实施各种措施来教育大众了解这种疾病、促进研究并透过加速提供更好的治疗方案来提供积极支持，正在推动市场成长。其他因素，包括新药批准的增加、医疗基础设施的快速改善、公众对神经系统疾病可用治疗方法的认识不断提高，以及与癫痫相关的耻辱感的减少，预计将推动市场成长。

本报告回答的关键问题：

迄今为止，全球癫痫药物市场表现如何，未来几年将如何表现？
全球癫痫药物市场的驱动因素、限制因素和机会是什么？
主要区域市场有哪些？
哪些国家代表了最具吸引力的癫痫药物市场？
根据世代类型，市场的划分是怎么样的？
根据抗癫痫药物类型，市场区隔是怎么样的？
基于配销通路的市场区隔是什么？
全球癫痫药物市场竞争格局如何？
全球癫痫药物市场的主要参与者/公司有哪些？

第一代药物
- 市场走向
- 关键环节
  - 苯妥英
  - 卡马西平
  - 奥卡西平
  - 丙戊酸
  - 乙舒酰亚胺
  - 扑米酮
  - 苯巴比妥
- 市场预测
第二代药物
- 市场走向
- 关键环节
  - 左乙拉西坦
  - 拉莫三嗪
  - 托吡酯
  - 普瑞巴林
  - 卢非酰胺
  - 唑尼沙胺
- 市场预测
第三代药物
- 市场走向
- 关键环节
  - 拉科酰胺
  - 吡崙帕奈
  - 醋酸艾斯利卡西平
  - 埃佐加滨/瑞替加滨
- 市场预测

第 7 章：市场细分：按抗癫痫药物类型

窄谱 AED
- 市场走向
- 市场预测
广谱 AED
- 市场走向
- 市场预测

第 8 章：市场区隔：按配销通路

医院药房
- 市场走向
- 市场预测
药局
- 市场走向
- 市场预测
其他的
- 市场走向
- 市场预测

第 9 章：市场区隔：按地区

北美洲
- 美国
  - 市场走向
  - 市场预测
- 加拿大
  - 市场走向
  - 市场预测
亚太
- 中国
  - 市场走向
  - 市场预测
- 日本
  - 市场走向
  - 市场预测
- 印度
  - 市场走向
  - 市场预测
- 韩国
  - 市场走向
  - 市场预测
- 澳洲
  - 市场走向
  - 市场预测
- 印尼
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
欧洲
- 德国
  - 市场走向
  - 市场预测
- 法国
  - 市场走向
  - 市场预测
- 英国
  - 市场走向
  - 市场预测
- 义大利
  - 市场走向
  - 市场预测
- 西班牙
  - 市场走向
  - 市场预测
- 俄罗斯
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
拉丁美洲
- 巴西
  - 市场走向
  - 市场预测
- 墨西哥
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
中东和非洲
- 市场走向
- 市场细分：按国家/地区
- 市场预测

第 10 章：驱动因素、限制与机会

概述
司机
限制
机会

第 11 章：价值链分析

第 12 章：波特五力分析

概述
买家的议价能力
供应商的议价能力
竞争程度
新进入者的威胁
替代品的威胁

第 13 章：价格分析

第14章：竞争格局

市场结构
关键参与者
关键参与者简介
- Abbott Laboratories
- Alkem Laboratories Limited
- Bausch Health Companies Inc.
- Eisai Co. Ltd.
- GSK plc
- H. Lundbeck A/S
- Jazz Pharmaceuticals plc
- Novartis AG
- Pfizer Inc.
- Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
- UCB SA

简介目录图表

Product Code: SR112024A6650

The global epilepsy drugs market size reached US$ 2.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.16% during 2024-2032. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global epilepsy drugs market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on generation type, anti-epileptics drugs type and distribution channel.

Generation Type Insights

First Generation Drugs

Phenytoin

Carbamazepine

Oxcarbazepine

Valproate

Ethosuximide

Primidone

Phenobarbital

Second Generation Drugs

Levetiracetam

Lamotrigine

Topiramate

Pregabalin

Rufinamide

Zonisamide

Third Generation Drugs

Lacosamide

Perampanel

Eslicarbazepine Acetate

Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

A detailed breakup and analysis of the epilepsy drugs market based on the anti-epileptics drugs type has also been provided in the report. This includes narrow and broad-spectrum AEDs. According to the report, broad-spectrum AEDs accounted for the largest market share.

Distribution Channel Insights

Hospital Pharmacy

Pharmacy Stores

Others

A detailed breakup and analysis of the epilepsy drugs market based on the distribution channel has been provided in the report. This includes hospital pharmacy, pharmacy stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global epilepsy drugs market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global epilepsy drugs market?
What are the key regional markets?
Which countries represent the most attractive epilepsy drugs markets?
What is the breakup of the market based on the generation type?
What is the breakup of the market based on the anti-epileptics drugs type?
What is the breakup of the market based on the distribution channel?
What is the competitive structure of the global epilepsy drugs market?
Who are the key players/companies in the global epilepsy drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Epilepsy Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Generation Type

6.1 First Generation Drugs
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Phenytoin
  - 6.1.2.2 Carbamazepine
  - 6.1.2.3 Oxcarbazepine
  - 6.1.2.4 Valproate
  - 6.1.2.5 Ethosuximide
  - 6.1.2.6 Primidone
  - 6.1.2.7 Phenobarbital
- 6.1.3 Market Forecast
6.2 Second Generation Drugs
- 6.2.1 Market Trends
- 6.2.2 Key Segments
  - 6.2.2.1 Levetiracetam
  - 6.2.2.2 Lamotrigine
  - 6.2.2.3 Topiramate
  - 6.2.2.4 Pregabalin
  - 6.2.2.5 Rufinamide
  - 6.2.2.6 Zonisamide
- 6.2.3 Market Forecast
6.3 Third Generation Drugs
- 6.3.1 Market Trends
- 6.3.2 Key Segments
  - 6.3.2.1 Lacosamide
  - 6.3.2.2 Perampanel
  - 6.3.2.3 Eslicarbazepine Acetate
  - 6.3.2.4 Ezogabine/Retigabine
- 6.3.3 Market Forecast

7 Market Breakup by Anti-Epileptics Drugs Type

7.1 Narrow-Spectrum AEDs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Broad-Spectrum AEDs
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacy
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Pharmacy Stores
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Alkem Laboratories Limited
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Bausch Health Companies Inc.
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Eisai Co. Ltd.
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 GSK plc
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 H. Lundbeck A/S
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Jazz Pharmaceuticals plc
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Novartis AG
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Pfizer Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 SWOT Analysis
- 14.3.11 UCB S.A.
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

简介目录图表

List of Figures

Figure 1: Global: Epilepsy Drugs Market: Major Drivers and Challenges
Figure 2: Global: Epilepsy Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Epilepsy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Epilepsy Drugs Market: Breakup by Generation Type (in %), 2023
Figure 5: Global: Epilepsy Drugs Market: Breakup by Anti-Epileptics Drugs Type (in %), 2023
Figure 6: Global: Epilepsy Drugs Market: Breakup by Distribution Channel (in %), 2023
Figure 7: Global: Epilepsy Drugs Market: Breakup by Region (in %), 2023
Figure 8: Global: Epilepsy Drugs (First Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Epilepsy Drugs (First Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Epilepsy Drugs (Second Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Epilepsy Drugs (Second Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Epilepsy Drugs (Third Generation Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Epilepsy Drugs (Third Generation Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Epilepsy Drugs (Hospital Pharmacy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Epilepsy Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Epilepsy Drugs (Pharmacy Stores) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Epilepsy Drugs (Pharmacy Stores) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Epilepsy Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Epilepsy Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: North America: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: North America: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: United States: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: United States: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Canada: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Canada: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Asia-Pacific: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Asia-Pacific: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: China: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: China: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Japan: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Japan: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: India: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: India: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: South Korea: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: South Korea: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Australia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Australia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Indonesia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Indonesia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Europe: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Europe: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Germany: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Germany: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: France: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: France: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: United Kingdom: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: United Kingdom: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Italy: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Italy: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Spain: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Spain: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: Russia: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: Russia: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Latin America: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Latin America: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Brazil: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Brazil: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Mexico: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Mexico: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Middle East and Africa: Epilepsy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Middle East and Africa: Epilepsy Drugs Market: Breakup by Country (in %), 2023
Figure 72: Middle East and Africa: Epilepsy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Global: Epilepsy Drugs Industry: Drivers, Restraints, and Opportunities
Figure 74: Global: Epilepsy Drugs Industry: Value Chain Analysis
Figure 75: Global: Epilepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Epilepsy Drugs Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Epilepsy Drugs Market Forecast: Breakup by Generation Type (in Million US$), 2024-2032
Table 3: Global: Epilepsy Drugs Market Forecast: Breakup by Anti-Epileptics Drugs Type (in Million US$), 2024-2032
Table 4: Global: Epilepsy Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 5: Global: Epilepsy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Epilepsy Drugs Market: Competitive Structure
Table 7: Global: Epilepsy Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219